

**THE REMARKS**

**The Amendments**

The amendments of Claim 1 is supported by page 8, 2<sup>nd</sup> paragraph, 1<sup>st</sup> sentence.

New Claim 20 is supported by page 16, first full paragraph, line 8.

No new matter is introduced in any of the amendments. The Examiner is requested to enter the amendments.

**The Response**

In response to the restriction requirement, Applicants are electing Group I, Claims 1-8, 13, 18 and 19, which are drawn to a bivalent or multivalent antibody that binds an epitope on CD3, and pharmaceutical compositions thereof, with traverse.

Holliger et al. (U.S. Patent No. 7,122,646, col. 55-56) discloses an anti-murine CD3 diabody in example 18. Holliger et al. only disclose a diabody with the specificity to murine CD3, and do not disclose the specificity to human CD3. Holliger et al further do not disclose any pharmaceutical utility of the diabodies. Therefore, the special technical features of the amended claims are not taught by Holliger et al.


In response to the species election requirement, Applicants are electing species C.

Claims 1-8, 13, 18 and 19, and the new Claim 20 read upon the elected species.

Upon the allowance of a generic claim, Applicant are entitled to consideration of claim to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141.

Date: June 6, 2008

Respectfully submitted,

  
\_\_\_\_\_  
Viola T. Kung, Ph.D. (Reg. No. 41,131)

HOWREY LLP  
2941 Fairview Park Drive, Box 7  
Falls Church, VA 22042  
Tel: (650) 798-3570  
Fax: (650) 798-3600